Prudential Financial
PLX icon

Prudential Financial’s Protalix BioTherapeutics PLX Stock Holding History

Prudential Financial’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Hold
10,110
– – ﹤0.01% 2469
2026
Q1 		$21.9K Buy
+10,110
New +$25.1K ﹤0.01% 2374
2025
Q2 		– Sell
-36,400
Closed -$93.2K – 2493
2025
Q1 		$93.2K Hold
36,400
– – ﹤0.01% 2136
2024
Q4 		$68.4K Buy
+36,400
New +$51.5K ﹤0.01% 2181

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Prudential Financial's PLX Position: Q2 2026 in Review

Prudential Financial held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 10,110 shares worth $23.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

Prudential Financial first reported a position in PLX in Q4 2024 and has held it in 4 quarters since. The position peaked at $93.2K in Q1 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Prudential Financial held 10,110 shares of Protalix BioTherapeutics worth $23.6K as of Q2 2026.
  • Prudential Financial left its Protalix BioTherapeutics share count unchanged in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2469 holding.
  • Prudential Financial first reported a position in Protalix BioTherapeutics in Q4 2024 and has held it in 4 quarters since.
  • Prudential Financial's Protalix BioTherapeutics position peaked at $93.2K in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.